Iterum Therapeutics announces Issuance of Allowance for a U.S. Patent Covering Oral Sulopenem
December 15, 2022 08:00 ET
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company” or “Iterum”), a clinical-stage pharmaceutical company focused on developing next...
Iterum Therapeutics Reports Third Quarter 2022 Financial Results
November 10, 2022 07:00 ET
|
Iterum Therapeutics plc
--Patient Enrollment in Registration Trial for uUTI Underway-- --Cash Runway into 2024-- DUBLIN, Ireland and CHICAGO, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM)...
Iterum Therapeutics to Provide Business Update and Report Third Quarter 2022 Financial Results on November 10, 2022
November 03, 2022 08:00 ET
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation...
Iterum Announces First Patient Dosed in REASSURE, a Phase 3 Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infections
October 20, 2022 07:30 ET
|
Iterum Therapeutics plc
-- NDA resubmission expected in Second Half of 2024, if successful-- --Oral sulopenem, if approved, could be the first antibiotic approved for uncomplicated urinary tract infections in over 25...
Iterum Therapeutics to Present Data at IDWeek 2022
October 17, 2022 17:19 ET
|
Iterum Therapeutics plc
Analysis of data from Phase 3 studies in uUTI and cUTI to assess the relevance of a positive urine culture in patients with no clinical symptoms after being treated for a UTINew data on the efficacy...
Iterum Therapeutics announces Issuance of Allowance for a U.S. Patent Covering Oral Sulopenem
September 19, 2022 07:30 ET
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, Sept. 19, 2022 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company” or “Iterum”), a clinical-stage pharmaceutical company focused on developing next...
Iterum Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference
September 07, 2022 09:15 ET
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation...
Iterum Therapeutics Regains Compliance with Nasdaq Bid Price Rule
September 01, 2022 16:15 ET
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next generation...
Iterum Therapeutics Announces Date of 1-for-15 Reverse Share Split
August 16, 2022 21:00 ET
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, Aug. 16, 2022 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next generation...
Iterum Therapeutics Reports Second Quarter 2022 Financial Results
August 12, 2022 07:00 ET
|
Iterum Therapeutics plc
--Enrollment in Registration Trial for uUTI to Begin Q4 2022-- --Cash Runway into 2024-- DUBLIN, Ireland and CHICAGO, Aug. 12, 2022 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq:...